AVI Biopharma is reporting that their Morpholino drug for Duchenne muscular dystrophy is successfully triggering dose-dependent exon-skipping in the early low-dose phase of their systemic trial. Doses of 2 and 4 mg/Kg induced exon skipping and higher dosing is ongoing.
Jon D. Moulton, Ph.D.
Gene Tools, LLC
Online Survey Software powered by Cvent
Board Rules | advertise | Privacy
Copyright © 2004-2012 Scientist Solutions, All Rights Reserved.Resources from NCBI used on this site.